Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,484 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Standard Scheduling Clear all

Conditions: Knee Osteoarthristis, ACL Injuries, Post-Traumatic
Interventions: extracorporeal shockwave therapy (ESWT), Sham Comparator; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 55 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer, Glioblastoma Multiforme, GBM, Brain Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Melanoma Recurrent, Prostate Cancer Metastatic, Recurrent Glioblastoma, Newly Diagnosed Glioblastoma
Interventions: ST101, Temozolomide, Radiation; Drug · Radiation
Lead sponsor: Sapience Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: San Francisco, California • Denver, Colorado • Warrenville, Illinois + 4 more

Conditions: Malignant Glioma, Glioblastoma
Interventions: MRZ, BEV; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 4
States / cities: Orange, California • Santa Monica, California • New York, New York + 1 more

Conditions: Acquired Immunodeficiency Syndrome (AIDS)
Interventions: AIDS EPC Package plus MI, Standard of Care (SOC); Behavioral · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pancreatic Adenocarcinoma Non-resectable
Interventions: PEGylated Recombinant Human Hyaluronidase (PEGPH20), Gemcitabine, Radiation; Drug · Radiation
Lead sponsor: Scripps Health; Other
Eligibility: Up to 90 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: La Jolla, California

Conditions: COVID-19
Interventions: Standard implementation webinar and online training, Virtual facilitation; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Overactive Bladder (OAB), Urge Incontinence
Interventions: onabotulinum toxin type a; Drug
Lead sponsor: Alexis Dieter; Other
Eligibility: 55 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Myeloid Leukemia (CML), Acute Myelogenous Leukemia (AML), Myelodysplastic Syndrome (MDS), Juvenile Myelomonocytic Leukemia (JMML), Acute Lymphoblastic Leukemia (ALL), Lymphoma (Hodgkin's and Non-Hodgkin's)
Interventions: CliniMACS CD34+ Reagent System, Thiotepa, Cyclophosphamide, Alemtuzumab, Tacrolimus, Melphalan, Busulfan, Fludarabine, Methylprednisolone; Device · Drug
Lead sponsor: Diane George; Other
Eligibility: Up to 22 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Telehealth, Health Behavior
Interventions: Less-is-better, Social proof, Endowment / decision staging, Standard email; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years to 88 Years
Enrollment: 14,099 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Mucositis
Interventions: Low Level Laser Therapy; Device
Lead sponsor: David A. Clump, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: EXTEND Plus, EXTEND; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 30 Years to 75 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Ovarian Neoplasms
Interventions: Pelvic imaging, Blood draw, Imaging guided biopsy, surgical biopsy or surgical excision; Procedure
Lead sponsor: Angle plc; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Epilepsy, SUDEP
Interventions: Fluoxetine, Placebo; Drug
Lead sponsor: Rup Kamal Sainju; Other
Eligibility: 18 Years to 75 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Iowa City, Iowa

Conditions: Amputation of Lower Limb Above Knee, Amputee, Amputation
Interventions: Bio Leg; Device
Lead sponsor: University of Florida; Other
Eligibility: 40 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Diabetic Retinopathy
Interventions: Non-mydriatic color fundus photography with the RetinaVue camera, Referral for dilated eye exam with an eye care professional; Diagnostic Test
Lead sponsor: Bassett Healthcare; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Cooperstown, New York

Conditions: Tobacco Dependence, Tobacco Smoking
Interventions: Smoke-free home resident intervention, Lay Health Worker coaching; Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 544 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Cranial Neurosurgery
Interventions: Brain imaging using transcranial focused ultrasound (tFUS); Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Vein Occlusion, Macular Degeneration Choroidal Neovascularization, Macular Edema, Diabetic Retinopathy
Interventions: Bromfenac Sodium 0.07%, Loteprednol Etabonate 0.38% Ophthalmic Gel/Jelly, Propylene Glycol Preservative-free Artificial Tears; Drug
Lead sponsor: Retina Research Institute, LLC; Other
Eligibility: 18 Years and older
Enrollment: 77 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Major Depressive Disorder
Interventions: Memantine; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 55 Years to 89 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Belmont, Massachusetts

Conditions: Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
Interventions: SEphB4-HSA, Pembrolizumab, Gemcitabine, Cisplatin, Enfortumab vedotin; Drug
Lead sponsor: Vasgene Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 700 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Prostate Cancer
Interventions: Proactive Streamlined Genetic Education and Testing, Usual Care; Behavioral
Lead sponsor: Georgetown University; Other
Eligibility: 21 Years to 80 Years · Male only
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Best Practice, Ibrutinib, Patient Derived Xenograft, Personalized Medicine; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pouchitis
Interventions: Low FODMAP Diet, Regular Diet; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Anemia, Fatigue, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Weekly procrit dosing, Interval Dosing; Drug
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Treatment of Post Traumatic Knee Osteoarthritis With Extracorporeal Shockwave Therapy

A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Living Well Project for Persons With AIDS

PEGPH20 Plus Gemcitabine With Radiotherapy in Patients With Localized, Unresectable Pancreatic Cancer

COVID-19 Vaccine Hesitancy Counseling Intervention for Pharmacists: A Stepped-Wedge Trial

Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Email Campaign to Increase Uptake of myGeisinger

Low-Level Laser Therapy for Prevention of Oral Mucositis

Expanding Technology-Enabled Nurse Delivered Chronic Disease Care

Evaluation of Multiple Protein and Molecular Biomarkers to Estimate Risk of Cancer in Gynecology Patients Presenting With a Pelvic Mass.

Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI

Bio Leg: Advancing Mobility (BAM)

RetinaVue Diabetic Screening

Smoke-free Home Study in Subsidized Housing

Feasibility of Transcranial Focused Ultrasound to Measure Brain Tumor

Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period

Treatment Resistant Geriatric Depression in Primary Care

Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors

Streamlined Genetic Testing in Prostate Cancer

Patient-Derived Xenografts in Personalizing Treatment for Patients With Relapsed/Refractory Mantle Cell Lymphoma

Treating Chronic Pouchitis With a Low FODMAP Diet

Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer